Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/8344
Full metadata record
DC FieldValueLanguage
dc.rights.licenseopenAccess-
dc.contributor.authorRadoičIc M.-
dc.contributor.authorBožovic B.-
dc.contributor.authorIlić K.-
dc.contributor.authorJankovic, Slobodan-
dc.contributor.authorAnÐelković J.-
dc.contributor.authorKostic M.-
dc.date.accessioned2020-09-19T15:28:48Z-
dc.date.available2020-09-19T15:28:48Z-
dc.date.issued2019-
dc.identifier.issn0870-399X-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/8344-
dc.description.abstract© Ordem dos Médicos 2019. Introduction: Chronic diseases with disabilities have a huge pharmacoeconomic impact on the health budget, especially in countries with recent history of social and economic transition. The aim of this study was to identify total costs of treating patients with lumbar pain in medical facilities in the central part of the Republic of Serbia. Material and Methods: This study was designed as a cost of illness study, using a bottom-up approach and it was conducted from a societal perspective. This study included 97 patients with lumbar syndrome who were treated in outpatient facilities in the Central part of Serbia. Results: Total costs of treating lumbar pain were about €200.40 ± €86.65 per patient per year, where the largest volume of direct costs were costs due to visits to specialists in primary health care institutions (€9.39 ± €6.66). Total indirect costs were €182.00 ± €78.66. Discussion: Our findings highlight the need to estimate the total costs of treating lumbar pain and evaluate the correlation between costs and other variables for larger population of these patients. Conclusion: This study distinguished two important pharmacoeconomic aspects of treating lumbar pain. Firstly, indirect costs represent major part of total costs of treating lumbar syndrome. Secondly, differences in valuing medical services between countries with recent history of social and economic transition and countries within European Union are one of crucial reasons for difference in total costs of treating low back pain among patients in neighboring regions.-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.sourceActa Medica Portuguesa-
dc.titlePharmacoeconomic aspects of low back pain treatment: Cost of illness study in the republic of Serbia-
dc.typearticle-
dc.identifier.doi10.20344/amp.10910-
dc.identifier.scopus2-s2.0-85065805226-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

573

Downloads(s)

55

Files in This Item:
File Description SizeFormat 
10.20344-amp.10910.pdf267.87 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons